Jemma Arakelyan: Honored to speak with Raju Kucherlapati during the BioHK24

Jemma Arakelyan shared on LinkedIn:

“I had the incredible honor of speaking with Dr. Raju Kucherlapati from Harvard Medical School during the BioHK24, City University of Hong Kong-Asian Fund for Cancer Research symposium!

His passion for research is truly inspiring. Dr. Raju Kucherlapati has made significant contributions across various fields, from gene targeting and homologous recombination to mapping the human genome – especially chromosome 12.

What struck me most was his dedication to developing techniques that modify genes in mammalian cells and his work on cloning human disease genes. It’s amazing to see how his efforts are shaping the future of genetics and medicine.

Thank you, Dr. Raju Kucherlapati, for sharing your insights and for all that you do to advance our understanding of human health!

Thanks for this great opportunity-Sujuan Ba and OncoDaily, Gevorg Tamamyan.”

Source: Jemma Arakelyan/LinkedIn

More posts featuring Jemma Arakelyan and Raju Kucherlapati on oncodaily.com
Jemma Arakelyan Interviews Raju Kucherlapati during the CityU-AFCR Symposium

Dr. Jemma Arakelyan is a medical oncologist and the chief executive officer of The Institute of Cancer and Crisis. She is a Ph.D. candidate at the City University of Hong Kong. Her research focuses on developing new anticancer treatments and understanding the underlying mechanisms of cancer progression. 

In addition to her academic pursuits, she is an active member of several scientific organizations, including the European School of Oncology (ESO), where she served as an ambassador in Armenia from 2020-2022. Dr. Arakelyan is also the president of the Institute of Cancer and Crisis. The Institute is dedicated to promoting awareness and support for cancer patients facing critical situations like war, pandemic, etc.

Dr. Kucherlapati is a Professor of Genetics and Medicine at Harvard Medical School. He obtained his PhD degree from the University of Illinois, trained at Yale University and was a faculty member at Princeton University, University of Illinois and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine. He joined the Harvard faculty in 2001 and was the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics.

His research interests are in the areas of human genetics, gene-modification, genomics and cancer genetics and genomics. He is a fellow of the American Association for the Advancement of Science and is a member of the National Academy of Medicine of the US. He was a member of a Presidential Committee during the administration of President Obama. He also founded several successful biotechnology companies